Journal
MOLECULAR CANCER
Volume 17, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12943-018-0759-3
Keywords
Chimeric antigen receptor T cell; Adoptive cell therapy; Solid tumor; Immunosuppressive microenvironment; Cancer immunotherapy
Categories
Funding
- State Key Laboratory of Natural Medicines [SKLNMBZ201403]
- National Science and Technology Major Projects of New Drugs in China [2012ZX09103301-004, 2014ZX09508007]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
Ask authors/readers for more resources
The potential for adoptive cell immunotherapy as a treatment against cancers has been demonstrated by the remarkable response in some patients with hematological malignancies using autologous T cells endowed with chimeric antigen receptors (CARs) specific for CD19. Clinical efficacy of CAR-T cell therapy for the treatment of solid tumors, however, is rare due to physical and biochemical factors. This review focuses on different aspects of multiple mechanisms of immunosuppression in solid tumors. We characterize the current state of CAR-modified T cell therapy and summarize the various strategies to combat the immunosuppressive microenvironment of solid tumors, with the aim of promoting T cell cytotoxicity and enhancing tumor cell eradication.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available